Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis
Executive Summary
FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies
You may also be interested in...
Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)